Tags

Type your tag names separated by a space and hit enter

Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
Vaccine. 2012 Feb 01; 30(6):1108-14.V

Abstract

A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥ 1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P=0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P=0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P=0.526) or the seroprotection rate (38.6% versus 48.3%, P=0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus.

Authors+Show Affiliations

Department of Medicine, Srinakharinwirot University, Royal Irrigation Hospital, 222, Tiwanon Road, Kwang Bangtalat, Pakkret, Nonthaburi, Thailand. lpaungpaga@yahoo.co.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22178515

Citation

Lertdumrongluk, Paungpaga, et al. "Safety and Immunogenicity of a 2009 Influenza a (H1N1) Vaccine in Hemodialysis Patients." Vaccine, vol. 30, no. 6, 2012, pp. 1108-14.
Lertdumrongluk P, Changsirikulchai S, Limkunakul C, et al. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine. 2012;30(6):1108-14.
Lertdumrongluk, P., Changsirikulchai, S., Limkunakul, C., Prachukthum, P., Punpiput, P., Buppanharun, R., & Chotpitayasunondh, C. (2012). Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine, 30(6), 1108-14. https://doi.org/10.1016/j.vaccine.2011.12.023
Lertdumrongluk P, et al. Safety and Immunogenicity of a 2009 Influenza a (H1N1) Vaccine in Hemodialysis Patients. Vaccine. 2012 Feb 1;30(6):1108-14. PubMed PMID: 22178515.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. AU - Lertdumrongluk,Paungpaga, AU - Changsirikulchai,Siribha, AU - Limkunakul,Chutatip, AU - Prachukthum,Poonsuk, AU - Punpiput,Prapaipun, AU - Buppanharun,Rungtiva, AU - Chotpitayasunondh,Chuencheevit, Y1 - 2011/12/15/ PY - 2011/09/13/received PY - 2011/11/29/revised PY - 2011/12/03/accepted PY - 2011/12/20/entrez PY - 2011/12/20/pubmed PY - 2012/5/17/medline SP - 1108 EP - 14 JF - Vaccine JO - Vaccine VL - 30 IS - 6 N2 - A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥ 1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P=0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P=0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P=0.526) or the seroprotection rate (38.6% versus 48.3%, P=0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22178515/Safety_and_immunogenicity_of_a_2009_influenza_A__H1N1__vaccine_in_hemodialysis_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(11)01946-3 DB - PRIME DP - Unbound Medicine ER -